The intersection of cutaneous lupus erythematosus (CLE) and osteonecrosis highlights a complex relationship between dermatologic and orthopedic pathology, underscoring the systemic nature of autoimmune disease. Osteonecrosis, characterized by ischemic bone death and subsequent joint degeneration, is a known complication in systemic lupus erythematosus (SLE), but emerging evidence suggests that CLE manifestations may serve as early indicators or contributory factors in its development. Chronic inflammation and microvascular injury, central to CLE pathophysiology, may predispose affected patients to compromised bone perfusion and ischemia, particularly in weight-bearing joints such as the hips and knees. Dermatologic signs, including persistent erythema, ulceration, or livedo reticularis, may reflect underlying vascular dysfunction that extends beyond the skin to subchondral bone, accelerating osteonecrotic processes. The role of autoantibodies, such as antiphospholipid antibodies, and their contribution to thrombotic microangiopathy in CLE further supports this potential mechanistic link. Early recognition of CLE-related vascular changes could guide orthopedic surveillance strategies, enabling timely imaging with MRI to detect early osteonecrosis before irreversible joint damage occurs. Therapeutic interventions for CLE, including corticosteroids and immunosuppressive agents, may inadvertently exacerbate osteonecrosis risk, necessitating careful balancing of treatment efficacy with preservation of joint health. Advances in vascular-targeted therapies and bone-preserving interventions, such as bisphosphonates or regenerative techniques, offer potential avenues for mitigating joint degeneration in this patient population. Understanding the bidirectional relationship between CLE and osteonecrosis provides an opportunity for dermatologists and orthopedists to collaborate on predictive, preventive, and therapeutic strategies that preserve joint function and improve quality of life for affected individuals.
References
[1]
Caramaschi, P., Biasi, D., Dal Forno, I. and Adami, S. (2012) Osteonecrosis in Systemic Lupus Erythematosus: An Early, Frequent, and Not Always Symptomatic Complication. AutoimmuneDiseases, 2012, Article ID: 725249. https://doi.org/10.1155/2012/725249
[2]
Dinkins, J., Slavinsky, V., Carney, B. and Frey, C. (2024) The Role of JAK Inhibitors in the Treatment of Cutaneous Lupus Erythematosus: A Review. JournalofDrugsinDermatology, 23, 1100-1107. https://doi.org/10.36849/jdd.8045
[3]
Rascu, A., Manger, K., Kraetsch, H., Kalden, J. and Manger, B. (1996) Review: Osteonecrosis in Systemic Lupus Erythematosus, Steroid-Induced or a Lupus-Dependent Manifestation? Lupus, 5, 323-327. https://doi.org/10.1177/096120339600500414
[4]
Shah, K.N., Racine, J., Jones, L.C. and Aaron, R.K. (2015) Pathophysiology and Risk Factors for Osteonecrosis. CurrentReviewsinMusculoskeletalMedicine, 8, 201-209. https://doi.org/10.1007/s12178-015-9277-8
[5]
Guo, L.N. and Nambudiri, V.E. (2020) Cutaneous Lupus Erythematosus and Cardiovascular Disease: Current Knowledge and Insights into Pathogenesis. ClinicalRheumatology, 40, 491-499. https://doi.org/10.1007/s10067-020-05257-3
[6]
Sayarlioglu, M., Yuzbasioglu, N., Inanc, M., Kamali, S., Cefle, A., Karaman, O., et al. (2010) Risk Factors for Avascular Bone Necrosis in Patients with Systemic Lupus Erythematosus. RheumatologyInternational, 32, 177-182. https://doi.org/10.1007/s00296-010-1597-9
[7]
Tse, S.M. and Mok, C.C. (2016) Time Trend and Risk Factors of Avascular Bone Necrosis in Patients with Systemic Lupus Erythematosus. Lupus, 26, 715-722. https://doi.org/10.1177/0961203316676384
[8]
Lin, J.H., Dutz, J.P., Sontheimer, R.D. and Werth, V.P. (2007) Pathophysiology of Cutaneous Lupus Erythematosus. ClinicalReviewsinAllergy&Immunology, 33, 85-106. https://doi.org/10.1007/s12016-007-0031-x
[9]
Merola, J.F., Nyberg, F., Franchimont, N., Barbey, C. and Werth, V.P. (2024) Editorial: Cutaneous Lupus Erythematosus Landscape: Pathophysiology, Unmet Needs, and Related Challenges in Clinical Practice. What Is on the Horizon? FrontiersinMedicine, 11, Article 1373552. https://doi.org/10.3389/fmed.2024.1373552
[10]
Miyagawa, F. (2023) Current Knowledge of the Molecular Pathogenesis of Cutaneous Lupus Erythematosus. JournalofClinicalMedicine, 12, Article 987. https://doi.org/10.3390/jcm12030987
[11]
Fetter, T., Braegelmann, C., de Vos, L. and Wenzel, J. (2022) Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus. FrontiersinMedicine, 9, Article 915828. https://doi.org/10.3389/fmed.2022.915828
[12]
Jones Jr., J.P. (1994) Concepts of Etiology and Early Pathogenesis of Osteonecrosis. Instructional Course Lectures, 43, 499-512. https://pubmed.ncbi.nlm.nih.gov/9097180/
[13]
Mont, M.A., Salem, H.S., Piuzzi, N.S., Goodman, S.B. and Jones, L.C. (2020) Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today? JournalofBoneandJointSurgery, 102, 1084-1099. https://doi.org/10.2106/jbjs.19.01271
[14]
Allen, C.S., Yeung, J.H., Vandermeer, B. and Homik, J. (2016) Bisphosphonates for Steroid-Induced Osteoporosis. Cochrane Database of Systematic Reviews, No. 10, CD001347. https://doi.org/10.1002/14651858.cd001347.pub2
[15]
Gupta, M. and Gupta, N. (2023) Bisphosphonate Related Jaw Osteonecrosis. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK534771/
[16]
Eppenberger, D., Nilius, H., Anagnostelis, B., Huber, C.A. and Nagler, M. (2022) Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-analysis. FrontiersinCardiovascularMedicine, 9, Article 883986. https://doi.org/10.3389/fcvm.2022.883986
[17]
McKay, L.I. and Cidlowski, J.A. (2003) Physiologic and Pharmacologic Effects of Corticosteroids. In: Kufe, D.W., Pollock, R.E., Weichselbaum, R.R., et al., Eds., Holland-Frei Cancer Medicine (6th Edition), BC Decker. https://www.ncbi.nlm.nih.gov/books/NBK13780/
Moya-Angeler, J. (2015) Current Concepts on Osteonecrosis of the Femoral Head. WorldJournalofOrthopedics, 6, 590-601. https://doi.org/10.5312/wjo.v6.i8.590
[20]
National Institute of Arthritis and Musculoskeletal and Skin Diseases (2023) Osteonecrosis (Avascular Necrosis) Symptoms & Causes. https://www.niams.nih.gov/health-topics/osteonecrosis
[21]
Zalavras, C.G. and Lieberman, J.R. (2014) Osteonecrosis of the Femoral Head: Evaluation and Treatment. JournaloftheAmericanAcademyofOrthopaedicSurgeons, 22, 455-464. https://doi.org/10.5435/jaaos-22-07-455
[22]
Karim, A.R., Cherian, J.J., Jauregui, J.J., Pierce, T. and Mont, M.A. (2015) Osteonecrosis of the Knee: Review. Annals of Translational Medicine, 3, Article 6. https://doi.org/10.3978/j.issn.2305-5839.2014.11.13
[23]
Hernigou, P., Hernigou, J. and Scarlat, M. (2020) Shoulder Osteonecrosis: Pathogenesis, Causes, Clinical Evaluation, Imaging, and Classification. OrthopaedicSurgery, 12, 1340-1349. https://doi.org/10.1111/os.12788
[24]
Rella, V., Rotondo, C., Altomare, A., Cantatore, F.P. and Corrado, A. (2022) Bone Involvement in Systemic Lupus Erythematosus. InternationalJournalofMolecularSciences, 23, Article 5804. https://doi.org/10.3390/ijms23105804
[25]
Salmon, J. and de Groot, P. (2008) Pathogenic Role of Antiphospholipid Antibodies. Lupus, 17, 405-411. https://doi.org/10.1177/0961203308090025
[26]
McCarthy, I. (2006) The Physiology of Bone Blood Flow: A Review. JournalofBoneandJointSurgery, 88, 4-9. https://doi.org/10.2106/jbjs.f.00890
[27]
Leone, P., Prete, M., Malerba, E., Bray, A., Susca, N., Ingravallo, G., et al. (2021) Lupus Vasculitis: An Overview. Biomedicines, 9, Article 1626. https://doi.org/10.3390/biomedicines9111626
[28]
Téllez Arévalo, A.M., Quaye, A., Rojas-Rodríguez, L.C., Poole, B.D., Baracaldo-Santamaría, D. and Tellez Freitas, C.M. (2022) Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. Medicina, 59, Article 56. https://doi.org/10.3390/medicina59010056
[29]
Verdelli, A., Corrà, A., Mariotti, E.B., Aimo, C., Ruffo di Calabria, V., Volpi, W., et al. (2022) An Update on the Management of Refractory Cutaneous Lupus Erythematosus. FrontiersinMedicine, 9, Article 941003. https://doi.org/10.3389/fmed.2022.941003
[30]
Nevskaya, T., Gamble, M.P. and Pope, J.E. (2017) A Meta-Analysis of Avascular Necrosis in Systemic Lupus Erythematosus: Prevalence and Risk Factors. Clinical and Experimental Rheumatology, 35, 700-710. https://pubmed.ncbi.nlm.nih.gov/28240590/
[31]
Jessop, S., Whitelaw, D.A., Grainge, M.J. and Jayasekera, P. (2017) Drugs for Discoid Lupus Erythematosus. CochraneDatabaseofSystematicReviews, No. 5, CD002954. https://doi.org/10.1002/14651858.cd002954.pub3
[32]
Egeberg, A., Schwarz, P., Harsløf, T., Andersen, Y.M.F., Pottegård, A., Hallas, J., et al. (2021) Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures. JAMADermatology, 157, 275-282. https://doi.org/10.1001/jamadermatol.2020.4968
[33]
Okon, L.G. and Werth, V.P. (2013) Cutaneous Lupus Erythematosus: Diagnosis and Treatment. BestPractice&ResearchClinicalRheumatology, 27, 391-404. https://doi.org/10.1016/j.berh.2013.07.008
[34]
Roenigk, H.H., Martin, J.S., Eichorn, P. and Gilliam, J.N. (1980) Discoid Lupus Erythematosus. Diagnostic Features and Evaluation of Topical Corticosteroid Therapy. Cutis, 25, 281-285. https://pubmed.ncbi.nlm.nih.gov/6987043/
[35]
Yokogawa, N., Eto, H., Tanikawa, A., Ikeda, T., Yamamoto, K., Takahashi, T., et al. (2017) Effects of Hydroxychloroquine in Patients with Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. Arthritis & Rheumatology, 69, 791-799. https://doi.org/10.1002/art.40018
[36]
Tsakonas, E., Joseph, L., Esdaile, J.M., Choquette, D., Senécal, J., Cividino, A., et al. (1998) A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus. Lupus, 7, 80-85. https://doi.org/10.1191/096120398678919778
[37]
Chasset, F., Arnaud, L., Costedoat-Chalumeau, N., Zahr, N., Bessis, D. and Francès, C. (2016) The Effect of Increasing the Dose of Hydroxychloroquine (HCQ) in Patients with Refractory Cutaneous Lupus Erythematosus (CLE): An Open-Label Prospective Pilot Study. JournaloftheAmericanAcademyofDermatology, 74, 693-699.e3. https://doi.org/10.1016/j.jaad.2015.09.064
[38]
Islam, M.N., Hossain, M., Haq, S.A., Alam, M.N., Ten Klooster, P.M. and Rasker, J.J. (2011) Efficacy and Safety of Methotrexate in Articular and Cutaneous Manifestations of Systemic Lupus Erythematosus. InternationalJournalofRheumaticDiseases, 15, 62-68. https://doi.org/10.1111/j.1756-185x.2011.01665.x
[39]
Keyes, E., Jobanputra, A., Feng, R., Grinnell, M., Vazquez, T., Diaz, D., et al. (2022) Comparative Responsiveness of Cutaneous Lupus Erythematosus Patients to Methotrexate and Mycophenolate Mofetil: A Cohort Study. JournaloftheAmericanAcademyofDermatology, 87, 447-448. https://doi.org/10.1016/j.jaad.2021.09.017
[40]
Callen, J.P. (1991) Azathioprine: An Effective, Corticosteroid-Sparing Therapy for Patients with Recalcitrant Cutaneous Lupus Erythematosus or With Recalcitrant Cutaneous Leukocytoclastic Vasculitis. ArchivesofDermatology, 127, 515-522. https://doi.org/10.1001/archderm.1991.04510010083008
[41]
Saavedra, M.Á., Sánchez, A., Morales, S., Ángeles, U. and Jara, L.J. (2015) Azathioprine during Pregnancy in Systemic Lupus Erythematosus Patients Is Not Associated with Poor Fetal Outcome. ClinicalRheumatology, 34, 1211-1216. https://doi.org/10.1007/s10067-015-2987-x
[42]
Gladman, D.D., Dhillon, N., Su, J. and Urowitz, M.B. (2017) Osteonecrosis in SLE: Prevalence, Patterns, Outcomes and Predictors. Lupus, 27, 76-81. https://doi.org/10.1177/0961203317711012
[43]
Cui, Q., Jo, W., Koo, K., Cheng, E.Y., Drescher, W., Goodman, S.B., et al. (2021) ARCO Consensus on the Pathogenesis of Non-Traumatic Osteonecrosis of the Femoral Head. JournalofKoreanMedicalScience, 36, e65. https://doi.org/10.3346/jkms.2021.36.e65
[44]
Shigemura, T., Nakamura, J., Kishida, S., Harada, Y., Ohtori, S., Kamikawa, K., et al. (2011) Incidence of Osteonecrosis Associated with Corticosteroid Therapy among Different Underlying Diseases: Prospective MRI Study. Rheumatology, 50, 2023-2028. https://doi.org/10.1093/rheumatology/ker277
[45]
Nawata, K., Nakamura, J., Ikeda, K., Furuta, S., Nakajima, H., Ohtori, S., et al. (2018) Transitional Changes in the Incidence of Osteonecrosis in Systemic Lupus Erythematosus Patients: Focus on Immunosuppressant Agents and Glucocorticoids. Rheumatology, 57, 844-849. https://doi.org/10.1093/rheumatology/key009
[46]
Hussein, S., Suitner, M., Béland-Bonenfant, S., Baril-Dionne, A., Vandermeer, B., Santesso, N., et al. (2018) Monitoring of Osteonecrosis in Systemic Lupus Erythema-tosus: A Systematic Review and Metaanalysis. The Journal of Rheumatology, 45, 1462-1476. https://doi.org/10.3899/jrheum.170837
[47]
Wei, Q., Zhou, M., Liu, J., Zhang, S., Gao, F., Lin, H., et al. (2021) Relationship between Osteonecrosis and Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review Protocol. BMJOpen, 11, e046163. https://doi.org/10.1136/bmjopen-2020-046163
[48]
McMahan, Z.H. and Wigley, F.M. (2010) Raynaud’s Phenomenon and Digital Ischemia: A Practical Approach to Risk Stratification, Diagnosis and Management. InternationalJournalofClinicalRheumatology, 5, 355-370. https://doi.org/10.2217/ijr.10.17
[49]
Sheikh, J.S., Retzinger, G.S. and Hess, E.V. (1998) Association of Osteonecrosis in Systemic Lupus Erythematosus with Abnormalities of Fibrinolysis. Lupus, 7, 42-48. https://doi.org/10.1191/096120398678919732
[50]
Fijałkowska, A., Kądziela, M. and Żebrowska, A. (2024) The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review. Journal of ClinicalMedicine, 13, Article 2419. https://doi.org/10.3390/jcm13082419
[51]
Oinuma, K., Harada, Y., Nawata, Y., Takabayashi, K., Abe, I., Kamikawa, K., et al. (2001) Osteonecrosis in Patients with Systemic Lupus Erythematosus Develops Very Early after Starting High Dose Corticosteroid Treatment. AnnalsoftheRheumaticDiseases, 60, 1145-1148. https://doi.org/10.1136/ard.60.12.1145
[52]
Nakamura, J., Ohtori, S., Sakamoto, M., Chuma, A., Abe, I. and Shimizu, K. (2010) Development of New Osteonecrosis in Systemic Lupus Erythematosus Patients in Association with Long-Term Corticosteroid Therapy after Disease Recurrence. Clinicaland Experimental Rheumatology, 28, 13-18. https://pubmed.ncbi.nlm.nih.gov/20346232/
[53]
Kaneko, K., Chen, H., Kaufman, M., Sverdlov, I., Stein, E.M. and Park‐Min, K. (2021) Glucocorticoid-Induced Osteonecrosis in Systemic Lupus Erythematosus Patients. ClinicalandTranslationalMedicine, 11, e526. https://doi.org/10.1002/ctm2.526
[54]
Li, D., Shamrock, A.G., Young, J.R., et al. (2024) Spontaneous Osteonecrosis of the Knee. StatPearls. https://www.ncbi.nlm.nih.gov/sites/books/NBK547722/
[55]
Ostendorf, B., Scherer, A., Specker, C., Mödder, U. and Schneider, M. (2003) Jaccoud’s Arthropathy in Systemic Lupus Erythematosus: Differentiation of Deforming and Erosive Patterns by Magnetic Resonance Imaging. Arthritis&Rheumatism, 48, 157-165. https://doi.org/10.1002/art.10753